• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge

tetano

Editor, Senior Moderator
J Med Virol


. 2024 Aug;96(8):e29877.
doi: 10.1002/jmv.29877. Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge

Akshay Binayke[SUP] 1 2 3 [/SUP], Aymaan Zaheer[SUP] 1 [/SUP], Siddhesh Vishwakarma[SUP] 1 [/SUP], Priyanka Sharma[SUP] 1 [/SUP], Jyotsna Dandotiya[SUP] 2 [/SUP], Sreevatsan Raghavan[SUP] 4 [/SUP], Mudita Gosain[SUP] 4 [/SUP], Savita Singh[SUP] 4 [/SUP], Souvick Chattopadhyay[SUP] 4 [/SUP], Jyotsana Kaushal[SUP] 1 [/SUP], Upasna Madan[SUP] 2 [/SUP], Pallavi Kshetrapal[SUP] 4 [/SUP], Gaurav Batra[SUP] 4 [/SUP], Nitya Wadhwa[SUP] 4 [/SUP], Anil Kumar Pandey[SUP] 5 [/SUP], Shinjini Bhatnagar[SUP] 4 [/SUP], Pramod Kumar Garg[SUP] 4 6 [/SUP], Amit Awasthi[SUP] 1 2 [/SUP]



Affiliations
Abstract

Emerging evidence shows increased humoral response post-omicron surge, but research on T cell responses is limited. This study investigated the durability, magnitude, and breadth of SARS-CoV-2-spike-specific T cell responses in 216 two-dose vaccinated individuals pre- and post-omicron surge. Post-surge samples showed enhanced T cell responses, indicating widespread asymptomatic exposure to omicron. Further analysis of 105 individuals with multiple exposures to SARS-CoV-2 through boosters or infections showed that post-omicron, two-dose vaccinated individuals had T cell responses comparable to those of COVID-19 convalescents or boosted individuals. Additionally, we report cross-reactive T cell responses against omicron sub-variants, including BA2.86, remained strong, with preserved frequencies of spike-specific stem-cell-like memory T cells. In silico prediction indicates that mutated epitopes of JN.1 and KP.2 retain over 95.6% of their HLA binding capability. Overall, our data suggests that T cell responses are sustained, enhanced, and cross-reactive against emerging SARS-CoV-2 variants following symptomatic or asymptomatic omicron infection.

Keywords: COVID‐19; KP.2; SARS‐CoV‐2 T cell; omicron surge; seronegative.

 
Back
Top Bottom